Tak1 inhibition has been considered a therapeutic option in colon, lung, and pancreatic cancers, entities that frequently exhibit KRAS mutations, which is based on the finding from preclinical models that Tak1 is exerting the prosurvival effects downstream of the rat sarcoma virus (RAS)/rapidly accelerated fibrosarcoma (RAF) signaling pathway [5]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.